Skip to main content

ImmunoPrecise Antibodies Ltd. (IPA)

NASDAQ: IPA · IEX Real-Time Price · USD
6.36 -0.18 (-2.75%)
Oct 21, 2021 4:00 PM EDT - Market closed
Market Cap121.31M
Revenue (ttm)14.75M
Net Income (ttm)-7.89M
Shares Out19.35M
EPS (ttm)-0.46
PE Ration/a
Forward PEn/a
Dividendn/a
Ex-Dividend Daten/a
Volume48,283
Open6.54
Previous Close6.54
Day's Range6.22 - 6.64
52-Week Range5.05 - 33.34
Beta-0.16
Analystsn/a
Price Targetn/a
Est. Earnings DateDec 9, 2021

About IPA

ImmunoPrecise Antibodies Ltd., together with its subsidiaries, engages in antibody production and related services in the United States, Canada, Europe, and internationally. The company offers a range of antibodies, enzymes, enzyme activity assays, arthritis animal products, proteins, deiminated proteins, organoid growth factors, and hybridoma products for research purposes. Its services include custom antigen modeling, design, and manufacturing; B cell sorting, screening, and sequencing; custom, immune, and naive phage display production and s...

IndustryBiotechnology
IPO DateJan 3, 2017
Employees73
Stock ExchangeNASDAQ
Ticker SymbolIPA
Full Company Profile

Financial Performance

In 2021, IPA's revenue was 17.91 million, an increase of 27.41% compared to the previous year's 14.06 million. Losses were -7.34 million, 48.4% more than in 2020.

Financial numbers in millions CADFinancial Statements

News

ImmunoPrecise Announces At-The-Market Facility of up to US$50 Million

VICTORIA, British Columbia--(BUSINESS WIRE)---- $IPA #Deltavariant--IMMUNOPRECISE ANTIBODIES LTD. (the “Company” or “IPA”) (NASDAQ: IPA) (TSX VENTURE: IPA), a leader in full-service therapeutic antibody...

1 week ago - Business Wire

Talem Therapeutics Announces Multi-Target Antibody Discovery Research Collaboration With Pierre Fabre

VICTORIA, British Columbia & CASTRES, France--(BUSINESS WIRE)---- $IPA #Deltavariant--IMMUNOPRECISE ANTIBODIES LTD. (the “Company” or “IPA”) (NASDAQ: IPA) (TSX VENTURE: IPA) and the Pierre Fabre pharmac...

2 weeks ago - Business Wire

ImmunoPrecise Reports Financial Results and Recent Business Highlights for First Quarter Fiscal Year 2022

VICTORIA, British Columbia--(BUSINESS WIRE)---- $IPA #Deltavariant--IMMUNOPRECISE ANTIBODIES LTD. (the “Company” or “IPA”) (NASDAQ: IPA) (TSX VENTURE: IPA), a leader in full-service therapeutic antibody...

1 month ago - Business Wire

ImmunoPrecise's Dutch Subsidiary Receives French Research Tax Credit (CIR) Accreditation

VICTORIA, British Columbia--(BUSINESS WIRE)---- $IPA #Deltavariant--IMMUNOPRECISE ANTIBODIES LTD. (the “Company” or “IPA”) (NASDAQ: IPA) (TSX VENTURE: IPA) a leader in full-service, therapeutic antibody...

1 month ago - Business Wire

ImmunoPrecise Announces Participation at the H.C. Wainwright 23rd Annual Global Investment Conference on September 13...

VICTORIA, British Columbia--(BUSINESS WIRE)---- $IPA #Deltavariant--IMMUNOPRECISE ANTIBODIES LTD. (the "Company" or "IPA") (NASDAQ: IPA) (TSX VENTURE: IPA), a leader in full-service, therapeutic antibod...

1 month ago - Business Wire

ImmunoPrecise Announces Participation at the H.C. Wainwright 23nd Annual Global Investment Conference on September 13...

VICTORIA, British Columbia--(BUSINESS WIRE)---- $IPA #Deltavariant--IMMUNOPRECISE ANTIBODIES LTD. (the "Company" or "IPA") (NASDAQ: IPA) (TSX VENTURE: IPA), a leader in full-service, therapeutic antibod...

1 month ago - Business Wire

ImmunoPrecise Reports Financial Results and Recent Business Highlights for First Quarter Fiscal Year 2022

VICTORIA, British Columbia--(BUSINESS WIRE)---- $IPA #Deltavariant--IMMUNOPRECISE ANTIBODIES LTD. (the "Company" or "IPA") (NASDAQ: IPA) (TSX VENTURE: IPA) a leader in full-service, therapeutic antibody...

1 month ago - Business Wire

ImmunoPrecise Welcomes Vice President of Client Relations and Vice President of Marketing to its Leadership Team, Acc...

VICTORIA, British Columbia--(BUSINESS WIRE)---- $IPA #Deltavariant--IMMUNOPRECISE ANTIBODIES LTD. (the “Company” or “IPA”) (NASDAQ: IPA) (TSX VENTURE: IPA) a leader in full-service, therapeutic antibody...

2 months ago - Business Wire

ImmunoPrecise Reports Financial Results and Recent Business Highlights for Full Fiscal Year 2021

VICTORIA, British Columbia--(BUSINESS WIRE)---- $IPA #Deltavariant--IMMUNOPRECISE ANTIBODIES LTD. (the “Company” or “IPA”) (NASDAQ: IPA) (TSX VENTURE: IPA) a leader in full-service, therapeutic antibody...

2 months ago - Business Wire

ImmunoPrecise SkyRockets On Delta Variant Therapy News: What's Next?

ImmunoPrecise Antibodies Ltd. (NASDAQ:IPA) skyrocketed 136% on Thursday after the company announced its TATX-03 PolyTope Therapy demonstrated potent pseudovirus neutralizing activity against the COVID-1...

2 months ago - Benzinga

IPA Stock: 7 Things to Know About Covid Vaccine Stock ImmunoPrecise as Shares Rocket 120%

Today's impressive move in ImmunoPrecise's stock price has led investors in IPA stock to consider what is driving these price changes. The post IPA Stock: 7 Things to Know About Covid Vaccine Stock Immu...

2 months ago - InvestorPlace

Why ImmunoPrecise Antibodies Stock Is Soaring Today

ImmunoPrecise Antibodies Ltd (NASDAQ:IPA) is surging higher Thursday after the company highlighted the ability of its antibody cocktail to potentially neutralize COVID-19 variants.  ImmunoPrecise Antibo...

2 months ago - Benzinga

Immunoprecise Stock Soars As COVID-19 Antibody Cocktail Shows Neutralizing Activity Against Delta Variant In Animal S...

Immunoprecise Antibodies Ltd (NASDAQ: IPA) has announced new results from its TATX-03 PolyTope Therapy, demonstrating potent pseudovirus neutralizing activity against the SARS-CoV-2 Delta (B.1.617.2) va...

2 months ago - Benzinga

ImmunoPrecise's PolyTope™ TATX-03 Antibody Cocktail Potently Neutralizes SARS-CoV-2 Delta Variant in in vitro Pseudov...

VICTORIA, British Columbia--(BUSINESS WIRE)---- $IPA #POLYTOPE--IMMUNOPRECISE ANTIBODIES LTD. (the "Company" or "IPA") (NASDAQ: IPA) (TSX VENTURE: IPA) today announced new results from its TATX-03 PolyT...

2 months ago - Business Wire

ImmunoPrecise to Report Financial Results and Business Highlights for Fiscal Year 2021

VICTORIA, British Columbia--(BUSINESS WIRE)---- $IPA #POLYTOPE--IMMUNOPRECISE ANTIBODIES LTD. (the "Company" or "IPA") (NASDAQ:IPA) (TSX VENTURE:IPA) a leader in full-service, therapeutic antibody disco...

3 months ago - Business Wire

Eurofins Discovery and ImmunoPrecise Announce Collaboration to Expand their Antibody Discovery Platform

VICTORIA, British Columbia--(BUSINESS WIRE)---- $ERF.PA #POLYTOPE--IMMUNOPRECISE ANTIBODIES LTD (the "Company" or "IPA") (NASDAQ: IPA) (TSX VENTURE: IPA) the market leader in full-service therapeutic di...

Other symbols:ERF
3 months ago - Business Wire

Histopathology Preclinical Data from ImmunoPrecise's Polytope™ Program Confirms Lung Inflammation Reduction

VICTORIA, British Columbia--(BUSINESS WIRE)---- $IPA #POLYTOPE--IMMUNOPRECISE ANTIBODIES LTD (the "Company" or "IPA") (NASDAQ: IPA) (TSX VENTURE: IPA) today announced additional results from its in vivo...

4 months ago - Business Wire

Preclinical Data from ImmunoPrecise's Drug Pipeline to be Presented During the BIO International Partnering Event

VICTORIA, British Columbia--(BUSINESS WIRE)---- $IPA #POLYTOPE--IMMUNOPRECISE ANTIBODIES LTD (the "Company" or "IPA") (NASDAQ: IPA) (TSX VENTURE: IPA) today announced the results from in vitro character...

4 months ago - Business Wire

ImmunoPrecise Announces Appointment of Dr. Ilse Roodink to the Role of Chief Scientific Officer and Resignation of Dr...

VICTORIA, British Columbia--(BUSINESS WIRE)---- $IPA #POLYTOPE--IMMUNOPRECISE ANTIBODIES LTD. (the "Company" or "IPA") (NASDAQ: IPA) (TSX VENTURE: IPA) a leader in full-service, therapeutic antibody dis...

4 months ago - Business Wire

ImmunoPrecise Names Dr. Dion Neame to Strategic Advisory Board

VICTORIA, British Columbia--(BUSINESS WIRE)---- $IPA #POLYTOPE--IMMUNOPRECISE ANTIBODIES LTD. (the "Company" or "IPA") (NASDAQ: IPA) (TSX VENTURE: IPA) a leader in full-service, therapeutic antibody dis...

4 months ago - Business Wire

ImmunoPrecise Moves SARS-CoV-2 PolyTope™ Cocktail Program's Path Toward IND Filing

VICTORIA, British Columbia--(BUSINESS WIRE)---- $IPA #POLYTOPE--ImmunoPrecise Antibodies Ltd. (the "Company" or "IPA") (NASDAQ: IPA) (TSX venture: IPA) announces the completion of an efficacy-driven, pr...

5 months ago - Business Wire

ImmunoPrecise Selects LifeSci Advisors as Investor Relations Agent of Record

VICTORIA, British Columbia--(BUSINESS WIRE)---- $IPA #POLYTOPE--IMMUNOPRECISE ANTIBODIES LTD. (the "Company" or "IPA") (NASDAQ: IPA) (TSX VENTURE: IPA) a leader in full-service, therapeutic antibody dis...

6 months ago - Business Wire

ImmunoPrecise Launches TATX-112 Antibody Program For Cancer, Alzheimer's Disease

ImmunoPrecise Antibodies Ltd's (NASDAQ: IPA) subsidiary Talem Therapeutics LLC has advanced developing a candidate referred to as TATX-112, against an undisclosed target, into formal lead candidate char...

6 months ago - Benzinga

ImmunoPrecise Launches TATX-112 Candidate Antibody Program, for the Treatment of Cancer and Alzheimer's Disease

VICTORIA, British Columbia--(BUSINESS WIRE)---- $IPA #POLYTOPE--IMMUNOPRECISE ANTIBODIES LTD. (the "Company" or "IPA") (NASDAQ: IPA) (TSX VENTURE: IPA) a leader in full-service, therapeutic antibody dis...

6 months ago - Business Wire

ImmunoPrecise Identifies a Unique Antibody, 23-H7, That Demonstrates In Vivo Efficacy, an Alternative Mechanism of Ac...

VICTORIA, British Columbia--(BUSINESS WIRE)---- $IPA #POLYTOPE--IMMUNOPRECISE ANTIBODIES LTD. (the "Company" or "IPA") (NASDAQ: IPA) (TSX VENTURE: IPA) a leader in full-service, therapeutic antibody dis...

6 months ago - Business Wire